Mie Hayashida1, Masanori Yasuo2, Masayuki Hanaoka3, Kuniaki Seyama4, Yoshikazu Inoue5, Koichiro Tatsumi6, Michiaki Mishima7. 1. First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. Electronic address: mie@shinshu-u.ac.jp. 2. First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. Electronic address: yasumasa@shinshu-u.ac.jp. 3. First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. Electronic address: masayuki@shinshu-u.ac.jp. 4. Division of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan. Electronic address: kseyama@juntendo.ac.jp. 5. Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan. Electronic address: giichi@kch.hosp.go.jp. 6. Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan. Electronic address: tatsumi@faculty.chiba-u.jp. 7. Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: mishima@kuhp.kyoto-u.ac.jp.
Abstract
BACKGROUND: In lymphangioleiomyomatosis (LAM), predicting lung disease progression is essential for treatment planning. However, no previous Japanese studies have attempted to predict the reductions in pulmonary function that occur in LAM patients. METHODS: The data for 89 LAM patients who had undergone ≥3 spirometry tests and whose data had been registered in the Japanese National Research Project on Intractable Diseases database between October 2009 and March 2014 were analyzed after excluding patients who had undergone (1) a lung transplant; (2) mTOR inhibitor treatment; or (3) thoracic drainage, pleurodesis, surgery, or thoracic duct ligation during the study period. The rates of change (slope) in pulmonary parameters were calculated, and their associations with clinical background factors were investigated. RESULTS: Among the whole study population, the median (quartiles) slope of forced expiratory volume in one second (FEV1) was -46.7 (-95.2; -15.0)mL per year. Episodes of conservatively treated pneumothorax during the study period were found to be associated with rapid reductions in FEV1 (% predicted). Pregnancy during the study period was associated with a reduction in FEV1 (% predicted). When the patients were divided into those who exhibited initial FEV1 (% predicted) values of >70% (Group A) and ≤70% (Group B), Group B displayed significantly faster reductions in FEV1 (% predicted) than Group A. CONCLUSIONS: LAM patients whose initial FEV1 (% predicted) values are ≤70% subsequently exhibit rapid reductions in their FEV1 values, and hence, require treatment. However, the FEV1 reduction rate varies markedly among individuals and should be monitored in all cases.
BACKGROUND: In lymphangioleiomyomatosis (LAM), predicting lung disease progression is essential for treatment planning. However, no previous Japanese studies have attempted to predict the reductions in pulmonary function that occur in LAM patients. METHODS: The data for 89 LAM patients who had undergone ≥3 spirometry tests and whose data had been registered in the Japanese National Research Project on Intractable Diseases database between October 2009 and March 2014 were analyzed after excluding patients who had undergone (1) a lung transplant; (2) mTOR inhibitor treatment; or (3) thoracic drainage, pleurodesis, surgery, or thoracic duct ligation during the study period. The rates of change (slope) in pulmonary parameters were calculated, and their associations with clinical background factors were investigated. RESULTS: Among the whole study population, the median (quartiles) slope of forced expiratory volume in one second (FEV1) was -46.7 (-95.2; -15.0)mL per year. Episodes of conservatively treated pneumothorax during the study period were found to be associated with rapid reductions in FEV1 (% predicted). Pregnancy during the study period was associated with a reduction in FEV1 (% predicted). When the patients were divided into those who exhibited initial FEV1 (% predicted) values of >70% (Group A) and ≤70% (Group B), Group B displayed significantly faster reductions in FEV1 (% predicted) than Group A. CONCLUSIONS: LAM patients whose initial FEV1 (% predicted) values are ≤70% subsequently exhibit rapid reductions in their FEV1 values, and hence, require treatment. However, the FEV1 reduction rate varies markedly among individuals and should be monitored in all cases.
Authors: Nishant Gupta; Hye-Seung Lee; Lisa R Young; Charlie Strange; Joel Moss; Lianne G Singer; Koh Nakata; Alan F Barker; Jeffrey T Chapman; Mark L Brantly; James M Stocks; Kevin K Brown; Joseph P Lynch; Hilary J Goldberg; Gregory P Downey; Angelo M Taveira-DaSilva; Jeffrey P Krischer; Kenneth Setchell; Bruce C Trapnell; Yoshikazu Inoue; Francis X McCormack Journal: Eur Respir J Date: 2019-04-04 Impact factor: 16.671
Authors: Nishant Gupta; Hye-Seung Lee; Jay H Ryu; Angelo M Taveira-DaSilva; Gerald J Beck; Jar-Chi Lee; Kevin McCarthy; Geraldine A Finlay; Kevin K Brown; Stephen J Ruoss; Nilo A Avila; Joel Moss; Francis X McCormack Journal: Chest Date: 2018-06-22 Impact factor: 9.410
Authors: Shihwan Chang; Ji Soo Choi; Ah Young Leem; Su Hwan Lee; Sang Hoon Lee; Song Yee Kim; Kyung Soo Chung; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Jin Gu Lee; Hyo Chae Paik; Hyo Sup Shim; Eun Hye Lee; Moo Suk Park Journal: Sci Rep Date: 2022-05-18 Impact factor: 4.996